Search Results
Your search for The A,The A matches 32372 pages
Showing 27101 - 27150Using Electronic Health Records to Improve Communication With Patients
Clinicians may argue that electronic health records (EHRs) interfere with the patient-physician relationship, and patients may complain about “distracted doctors,” too busy with computer screens to make eye contact, but according to Thomas W. LeBlanc, MD, MA, of Duke University School of Medicine...
Drew Pinsky, MD, Elected to Prostate Cancer Foundation Board of Directors
The Prostate Cancer Foundation has announced that Drew Pinsky, MD, has been elected to the Foundation’s Board of Directors. Dr. Pinsky, a cancer survivor, is a Practicing Physician and a Member of the Staff of Huntington Memorial Hospital in Pasadena, California. He is also Assistant Clinical...
Gene Therapy Betters Chemotherapy Tolerance, Effectiveness in Small Glioblastoma Study
Using gene therapy and a combination of chemotherapy drugs, researchers at Fred Hutchinson Cancer Research Center have been able to enhance the tolerance and effectiveness of medications used in treating glioblastoma while also protecting healthy cells from their toxic effects. The report,...
Ongoing Clinical Trials Actively Recruiting Patients With Intraocular Cancer
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies of children and adults with intraocular cancers. The studies include pilot, phase 0, phase I, phase II, and observational trials evaluating new combination therapies, vaccines, optical...
Moffitt Appoints Louis B. Harrison, MD, New Chair, Radiation Oncology
Louis B. Harrison, MD, has joined Moffitt Cancer Center in Tampa as Chair of the Department of Radiation Oncology, and Senior Member. Moffitt’s Radiation Oncology program includes faculty of cancer specialists who provide comprehensive cancer care for tumors at all anatomical locations, as well as...
UNC Lineberger Secures Three Major NCI Grants to Advance the Nation’s Clinical Trials Program
At the national level, clinical trials are seeing a lot of change. In an effort to increase efficiency and keep up with national changes in the types of clinical trials offered to cancer patients, the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN) is undergoing a major...
Immunotherapy Research of James P. Allison, PhD, Has Led to a Paradigm Shift in the Treatment of Cancer
James P. Allison, PhD, has been bucking the status quo since he was a teenager growing up in the small agricultural town of Alice, Texas, in the 1950s and 1960s. He first butted heads with authority figures when he was in high school and learned that his biology class had omitted the teaching of...
Expert Point of View: Karla Kerlikowske, MD
In an accompanying editorial,1 Karla Kerlikowske, MD, of the University of California, San Francisco, and colleagues point out that while the finding of Killelea et al that digital mammography screening was not associated with downstaging of disease may not be surprising, given the similar accuracy ...
Study Finds Increased Breast Cancer Screening Costs in Medicare Population but No Increase in Cancer Detection
In a study of the use of breast cancer screening modalities in the Medicare population reported in Journal of the National Cancer Institute, Brigid K. Killelea, MD, MPH, FACS, and colleagues at Yale University School of Medicine, Yale Cancer Center, and Yale–New Haven Hospital, New Haven,...
Breast Cancer Screening Using Tomosynthesis in Combination With Digital Mammography
In a study reported in JAMA and reviewed in this issue of The ASCO Post, Friedewald and colleagues1 showed that the addition of tomosynthesis to digital mammography2 resulted in a decrease in the screening recall rate3 and an increase in the cancer detection rate.4,5 This retrospective analysis of...
Adding Tomosynthesis to Digital Mammography Decreased Recall Rate, Increased Cancer Detection Rate in Breast Cancer Screening
In a large multicenter study reported in JAMA, Sarah M. Friedewald, MD, of the Advocate Lutheran General Hospital, Center for Advanced Care, Park Ridge, Illinois, and colleagues found that use of tomosynthesis plus digital mammography reduced the recall rate and increased the cancer detection rate...
National Cancer Institute Launches the National Clinical Trials Network to Expedite Scientific Advances
In March, the National Cancer Institute (NCI) transformed its Cooperative Group Program into the National Clinical Trials Network (NCTN). Spurred by recommendations in the Institute of Medicine (IOM) 2010 report, A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI...
NIH Launches Human Safety Study of Ebola Vaccine Candidate
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched initial human testing of an investigational vaccine to prevent Ebola virus disease, according to a news release issued by NIH. The early-stage trial has begun initial human...
Kenneth S. Ramos, MD, PhD, PharmB, Named New MD-PhD Head at University of Arizona College of Medicine, Tucson
Kenneth S. Ramos, MD, PhD, PharmB, has been named the new MD-PhD Program Director at the University of Arizona College of Medicine, Tucson. The Program was established in 1990 to provide dual training in medicine and research to students interested in careers as research-intensive physicians...
Timing and Meaning of Do-Not-Resuscitate Orders in the Palliative Care Setting
Although a do-not-resuscitate (DNR) order does not mean “do not treat,” that is how it is often interpreted, according to a study examining the level of care oncology inpatients at a tertiary care hospital received.1 The study found that the interpretation of DNR orders among oncology nurses and...
New Cancer.Net Fact Sheets Now Available for Your Practice
Be sure to check out Cancer.Net’s latest ASCO Answers fact sheet titles on hereditary breast and ovarian cancer and metastatic breast cancer. These one-page (front and back) introductions to a variety of topics include an overview, illustrations, terms to know, and questions to ask the doctor. Find ...
ASCO University’s New Cancer Genetics Program
Over the past decade, ASCO has launched multiple initiatives on cancer genetics that complement the rapid progress in the field. These initiatives have resulted in educational offerings and policy recommendations that have improved both preventive and therapeutic options for patients with cancer...
September Is Conquer Cancer Foundation Challenge Month
At the 50th Annual Meeting of the American Society of Clinical Oncology, Conquer Cancer Foundation Board Member Raj Mantena, RPh, announced that for the coming year he would match individual donations to the Conquer Cancer Foundation up to $1 million, allowing meeting attendees the opportunity to...
ASCO to Participate in 2014 Rally for Medical Research Hill Day
ASCO volunteers will be participating in the Rally for Medical Research Hill Day in Washington, DC, on September 18 to help bring attention to the need for a sustained federal investment in the National Institutes of Health. This will be the second year that ASCO, a gold sponsor of the event and...
CMS Approval, New Platform Making QOPI® Participation Easier
ASCO’s Quality Oncology Practice Initiative (QOPI®) is transforming to meet the reporting needs of its members. The approval of new reporting pathways by the Centers for Medicare and Medicaid Services (CMS), along with a new QOPI platform, will offer new opportunities for practices participating or ...
A Vision That Endured: Celebrating ASCO’s Founders
As 2014 marks the 50th Anniversary of the founding of the American Society of Clinical Oncology (ASCO), it seems only appropriate to highlight the founders of the Society and the vision they shared for its future. The 1960s were the early days of the use of chemotherapy for the treatment of cancer, ...
Issue Highlights
Career and Training Transitioning From Fellowship to Career: Expectations vs Reality Start Expanding Your Oncology Network Today: Five Tips to Get You Networking Mentoring for New Community Physicians: The Toledo Clinic Experience Don’t Call Your Program Director “Dude”… and Other Tips for...
ASCO Launches New Publication for Oncology Trainees and Early-Career Professionals
In February 2014, ASCO launched a new member publication, ASCO Connection: Trainee & Early-Career Oncologists. This quarterly magazine-style publication is dedicated to topics of interest to medical students, interns, residents, fellows, and junior faculty. All ASCO Student/Non-Oncology...
CDC’s Breast and Cervical Screening Program Benefits Millions of Underserved Women in the United States
More than 4.3 million women with limited access to health care received breast and cervical cancer screening and diagnostic services in the first 20 years of the Centers for Disease Control and Prevention (CDC) National Breast and Cervical Cancer Early Detection Program. From 1991 to 2011, 56,662...
Complications No Different Between Open and Robot-Assisted Radical Cystectomy When Open Urinary Diversion Performed
We read the letter to the editor in the July 24, 2014, issue of The New England Journal of Medicine entitled, “A Randomized Trial of Robot-Assisted Laparoscopic Radical Cystectomy,” with great interest.1 Provocative Results In the letter, reviewed in this issue of The ASCO Post, Bochner and...
No Difference in Complication Rates or Hospital Stay With Robot-Assisted vs Open-Surgery Cystectomy in Bladder Cancer
Retrospective analyses indicate that robot-assisted laparoscopic surgery for radical cystectomy in patients with bladder cancer is associated with reduced risk of complications and shorter hospital stay compared with open surgery. In a small single-institution randomized trial reported in a letter...
City of Hope Investigator Receives Grant for Immunotherapy Research
The Damon Runyon Cancer Research Foundation has awarded a $450,000 grant to an investigator studying T cells at City of Hope in Duarte. Elizabeth Budde, MD, PhD, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, Duarte, received The Jake...
Rwanda Offers Women Free Cervical Cancer Screening, HPV Vaccination
Cervical cancer is one of the major killers among women in Rwanda, and with the support of Rwanda’s First Lady, Jeannette Kagame, the country is rolling out a free human papillomavirus (HPV) vaccination and cervical cancer screening program in collaboration with Marck, Qiagen (a Dutch...
NCCN Marks 20 Years of Evidence-Based Decision-Making in Small Cell Lung Cancer
The National Comprehensive Cancer Network (NCCN) recently announced publication of the 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC). One of the eight original NCCN Guidelines, the NCCN Guidelines for SCLC was initially...
PALB2 Study: Researchers and Patients Must 'Pal' for Progress
The recent publication by Antoniou et al on risk of breast cancer in PALB2 carriers,1 reviewed in this issue of The ASCO Post (page 47), is a contribution to the interesting history of the PALB2 gene, and an important milestone in the expansion of hereditary cancer susceptibility testing in the...
Study Quantifies Risk of Hereditary Breast Cancer in Carriers of PALB2 Mutations
In a study reported in The New England Journal of Medicine, Antonis C. Antoniou, PhD, Reader in Cancer Risk Prediction and Cancer Research UK Senior Cancer Research Fellow at the University of Cambridge, and colleagues identified lifetime risk of breast cancer in families with germline...
Patient-Reported Outcomes in Hematology and Oncology Product Development
INSIDE THE BLACK BOX is an occasional column providing insight into the U.S. Food and Drug Administration (FDA) and its policies and procedures. In this installment, Virginia Kwitkowski, MS, RN, ACNP-BC, and Elektra Papadopoulos, MD, MPH, discuss FDA’s current approach to the review of study...
Researchers at University of Michigan Receive $2.3 Million Grant to Promote Safety, Reduce Exposure Risk, at Chemotherapy Infusion Sites
Researchers at the University of Michigan School of Nursing and Comprehensive Cancer Center have received a $2.3 million grant to study oncology nurses’ exposure to hazardous drugs, including identifying ways to reduce exposure. “There are significant acute and long-term side effects from hazardous ...
Fox Chase Cancer Center Announces New Staff
Fox Chase Cancer Center has announced the appointment of two staff to the Center’s Department of Radiation Oncology and Surgical Oncology, respectively. Mark A. Hallman, MD, PhD, joins the Department of Radiation Oncology having served there recently as the Department’s Chief Resident. Sanjay S....
Lung Cancer Webinar Highlights Brain Metastases and Thoracic Radiotherapy
Postoperative radiation therapy, given after adjuvant chemotherapy, significantly increased overall survival in non–small cell lung cancer (NSCLC) compared to chemotherapy alone, according to a study reported at ASCO’s 2014 Annual Meeting.1 That study, an analysis of records in the National Cancer...
Optimal Chemoradiotherapy Dosing and Recurrence After Stereotactic Body Radiotherapy Explored in Lung Cancer Webinar
Cetuximab (Erbitux) added no survival benefit to chemoradiation in stage III non–small cell lung cancer (NSCLC), according to results reported in a Plenary Session of the 2013 World Conference on Lung Cancer in Sydney, Australia.1 It was the second surprise result from the Radiation Therapy...
2014 Lasker Award
The Albert and Mary Lasker Foundation has announced Mary-Claire King, PhD, of the University of Washington, Seattle, will receive the 2014 Lasker~Koshland Special Achievement Award for her contributions to medical science and human rights. Dr. King’s demonstration of the existence of familial...
Angiogenesis in Ovarian Cancer: Are We Missing the Clinical Target?
Production of vascular endothelial growth factor (VEGF) is increased during normal ovulation, and can account for much of the reversible toxicity associated with ovarian hyperstimulation.1,2 We also have compelling data from multiple clinical trials to validate the importance of tumor-associated...
Adding Antiangiopoietin Agent Trebananib to Paclitaxel Improves Progression-Free Survival in Recurrent Epithelial Ovarian Cancer
Trebananib inhibits angiogenesis by blocking the binding of angiopoietins 1 and 2 to the Tie2 receptor expressed on endothelial cells, a mechanism that differs from vascular endothelial growth factor (VEGF) inhibitors and that involves a different signaling pathway. In the phase III TRINOVA-1 trial ...
Early Study Finds Olaparib Tablet Safe in Pretreated Ovarian Cancer Patients; More Effective in Those With BRCA Mutations
An oral tablet form of a poly-ADP ribose polymerase (PARP) inhibitor, olaparib, given in combination with chemotherapy, was safe in heavily pretreated patients with ovarian cancer, and patients with BRCA mutations may have a better response compared with those without a BRCA mutation, according to...
PSA—It Just Keeps Getting Better, So Why Should It Stand Alone?
The updated results of the European Randomised Study of Screening for Prostate Cancer (ERSPC)—reported in The Lancet by Fritz H. Schröder, MD, of Erasmus University Medical Center, and colleagues1 and reviewed in this issue of The ASCO Post—show a continued decline, as predicted,2 in the number...
European Researchers at 13-Year Follow-up: Increased Absolute Benefit of PSA Screening in Prostate Cancer Mortality, but Time for Population-Based Screening Has Not Arrived
The 13-year follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC), reported by Fritz H. Schröder, MD, PhD, Professor Emeritus of Urology at Erasmus University Medical Center, Rotterdam, the Netherlands, and colleagues in The Lancet, showed that prostate-specific...
Novel Immunotherapy for Ovarian Cancer Receives Fast Track Designation
The U.S. Food and Drug Administration (FDA) has granted fast track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin for the treatment of women with ovarian cancer whose disease has progressed on or recurred after...
FDA Approves Pembrolizumab for Advanced Melanoma
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to the anti–PD-1 antibody pembrolizumab (Keytruda) for the treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs. Pembrolizumab is intended for use following treatment...
‘Paradigm-Shifting’ Results in Treatment of Hematologic Disorders
The three leukemia/lymphoma studies selected from the many 2014 ASCO Annual Meeting abstracts for presentation at the recent Best of ASCO meeting in Chicago “are really paradigm-shifting,” noted Lucy A. Godley, MD, PhD, of the University of Chicago. These studies, she said, “give great promise for...
What Constitutes High-Volume/Extensive Disease?
"I'm not sure what extensive disease really is, but in some patients, when you see it, you really recognize it. In other patients, it’s not 100% clear,” Dr. Yu commented (Fig. 1). Some patients with multiple medium or large lesions in bone would clearly meet the definition used in the CHAARTED...
Pros and Cons of Early Chemohormonal Therapy
There is considerable debate about moving chemohormonal therapy to an earlier point in the treatment of prostate cancer, at the time of initial diagnosis of metastases, according to Dr. Yu. In the pro column, “You might hit those de novo testosterone-independent clones if they exist.” Additionally, ...
When Should Chemotherapy Be Used in Metastatic Prostate Cancer?
Questions abound when it comes to the optimal timing and sequencing of chemotherapy in metastatic prostate cancer, according to Dr. Yu. For example, arguments could be made both for using it earlier, while disease is still hormone-sensitive, or later, after hormonal resistance emerges. “For...
Studies Help Refine Management of Prostate Cancer
Several studies reported at this year’s ASCO Annual Meeting address gray areas in the management of prostate cancer, according to Evan Y. Yu, MD, Associate Professor at the University of Washington and the Seattle Cancer Care Alliance. “In prostate cancer, probably the most excitement has happened...
In Managing Ovarian Cancer, Precision Medicine Is a Work in Progress
Precision medicine in the management of ovarian cancer “is a work in progress, to be sure,” Steven B. Newman, MD, noted in wrapping up the session on gynecologic cancer at the recent Best of ASCO meeting in Chicago. “A list of different histologic types of ovarian cancer and potential targets are...
